<DOC>
	<DOCNO>NCT03091920</DOCNO>
	<brief_summary>To compare safety , tolerability , pharmacokinetic ( PK ) profile , pharmacodynamic ( PD ) effect 2 treatment regimen IW-1973 Tablet ( 40 mg per day ) administer orally 2 week patient stable type 2 diabetes mellitus hypertension .</brief_summary>
	<brief_title>Trial IW-1973 , A Stimulator Soluble Guanylate Cyclase ( sGC ) Patients With Stable Type 2 Diabetes Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patient ambulatory male female Patient 's body mass index score &gt; 20 &lt; 40 kg/m2 Screening Visit Women childbearing potential must negative pregnancy test time screen checkin must agree use protocolspecified contraception throughout duration study Patient 's health stable clinically significant finding physical examination Patient type 2 ( ie , adult onset ) diabetes mellitus diagnose physician nurse practitioner &gt; 6 month Screening Visit , stable glycemic control medication , protocol specify HbA1c value Screening Visit Patient hypertension diagnose physician nurse practitioner &gt; 6 month Screening Visit , BP within protocol 's acceptable range Patients must stable regimen hypertension control include angiotensin convert enzyme inhibitor ( ACEi ) angiotensin receptor blocker ( ARB ) Other inclusion criterion per protocol Patient clinically significant active unstable medical condition , opinion Investigator , would preclude trial participation Patient medication ( ) , coadministered soluble guanylate cyclase ( sGC ) stimulator , could increase risk hypotension Patient evidence severe active endorgan damage Patient active smoker use nicotinecontaining product ( cigarette , ecigarettes , vape pen , cigar , chew tobacco , gum , patch ) 6 month Checkin . Use nicotine exclude study End Trial Visit . Other exclusion criterion per protocol</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>